Specialty drugs, high-cost, complex medications typically used for chronic, rare, or oncology conditions, now represent more than 50% of total pharmacy spend for most plans, despite being less than 2% of prescription volume. That spend grew roughly 18% in 2024 alone, far outpacing inflation. For a 5,000-life plan, specialty drug spend often runs $4–$8 million per year, and the year-over-year increase exceeds the entire generic and brand-retail savings most plans capture from any other intervention.
The financial scale of specialty makes it the single most important pharmacy benefit category to actively manage. These five questions surface the levers that matter.
Question 1: What's our specialty drug definition, and who controls it?
Most PBM contracts let the PBM define what counts as "specialty." The PBM's specialty list is typically internal, opaque, and updated unilaterally. Drugs move on and off the list at the PBM's discretion. This matters because specialty drugs are priced differently than non-specialty (often with deeper AWP discounts but lower or zero dispensing fees), and rebates are calculated separately for specialty claims.
When the PBM controls the definition, the PBM controls the economics. A drug that moves from "Brand Retail" to "Specialty" can shift the plan's pricing by 4–6 percentage points of AWP, plus changes in rebate eligibility.
The fix: Tie your specialty definition to a published, third-party specialty drug list (CMS publishes one, and AAHP/AHIP maintains one). Limit the PBM's discretion to add drugs not on the third-party list. Audit the list quarterly to catch unauthorized additions.
Question 2: What's our channel mix, pharmacy benefit vs medical benefit?
Specialty drugs can be paid under the pharmacy benefit (filled by a specialty pharmacy, dispensed to the patient) or under the medical benefit (administered by a physician in an office or infusion suite, billed as a Buy & Bill medical claim). The same drug can be paid through either channel, and the price difference can be 30% or more depending on the drug.
Pharmacy benefit pricing is usually transparent. Medical benefit pricing is buried in the ASP (Average Sales Price) plus a markup of 6% or more, with no direct rebate to the plan.
For most specialty drugs, pharmacy-benefit dispensing is cheaper for the plan. But some drugs are only available through medical benefit, some are clinically inappropriate for self-administration, and pharmacy-benefit dispensing requires the patient to navigate a specialty pharmacy.
The fix: Audit your specialty claims by channel. Identify drugs paid through medical benefit that could be moved to pharmacy benefit ("white-bagging" or "brown-bagging"). For drugs that have to stay on medical benefit, negotiate site-of-care optimization (home infusion or outpatient infusion center vs hospital outpatient department).
Question 3: Are we capturing manufacturer copay assistance correctly?
For high-cost specialty drugs, manufacturers often offer copay assistance programs that pay down the patient's out-of-pocket cost. These programs can be worth thousands of dollars per fill. The question is who captures the value.
Two common arrangements:
- Patient keeps the copay assistance. The plan pays its normal share, the patient's effective out-of-pocket goes to zero, and the manufacturer assistance offsets only the patient's cost. The plan sees no direct benefit.
- Copay maximizer / accumulator programs. The plan or its PBM intercepts the manufacturer assistance and credits it to the plan rather than the patient. The patient still gets free drug, but the plan captures the value.
Maximizer/accumulator programs can save plans 20–40% on specialty drug spend, but they're legally and ethically complex. Some states restrict them.
The fix: Understand which copay assistance programs your specialty pharmacy participates in. Decide whether a maximizer or accumulator strategy fits your plan philosophy. If yes, implement it explicitly and document the savings.
Question 4: What are our prior authorization and step therapy criteria?
Specialty drug utilization management, prior authorization, step therapy, quantity limits, is the second-largest specialty cost lever after channel mix. Tightly written criteria can reduce inappropriate utilization by 5–15% without harming clinical outcomes. Loose criteria let high-cost drugs through without review.
Common questions to audit:
- Are PA criteria evidence-based and aligned with FDA labeling?
- Is step therapy required for branded specialty drugs when a biosimilar or older brand is available?
- Are quantity limits set to FDA-labeled dosing, not arbitrary "safe" overestimates?
- Are appeals being approved at rates consistent with the criteria's intent?
- Are PAs auto-renewing for chronic conditions, or being re-reviewed annually?
The fix: Get a copy of the PA criteria for your top 20 specialty drugs by spend. Have an independent clinical pharmacist review them against current evidence.
Question 5: Do we have a biosimilar strategy?
Biosimilars, near-identical copies of biologic drugs after the original's patent expires, typically cost 30–50% less than the reference biologic. The biosimilar market grew dramatically in 2023–2024 with the launch of Humira biosimilars, Stelara biosimilars (2025), and continued biosimilar competition in oncology.
For a plan with significant spend on Humira (adalimumab), Stelara (ustekinumab), Remicade (infliximab), or Avastin (bevacizumab), biosimilar substitution can save hundreds of thousands of dollars annually with no clinical compromise.
But biosimilar adoption isn't automatic. The PBM has to place the biosimilar at a preferred formulary tier, notify prescribers, coordinate with the specialty pharmacy, and handle patient communication.
The fix: Ask your PBM for a written biosimilar strategy. For each top-spend reference biologic, document which biosimilars are available, the formulary placement of each, the expected savings, and the timeline for transitioning current patients.
The takeaway
Specialty drug economics changed faster than most pharmacy benefit programs have updated. Plans that were built around the old reality of 20% specialty spend are leaving real money on the table when specialty is now 50% or more of total. These five questions, asked annually, surface the biggest levers.